Promoted Content
Promoted Content

Find Approved Oncology Drugs in Clinical Development in DENMARK

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Ixabepilone

            Therapeutic Area: Oncology Product Name: Ixempra

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Negma

            Deal Size: $1.1 million Upfront Cash: Undisclosed

            Deal Type: Agreement February 11, 2021

            Details:

            This financing, under the called tranche, serves as a foundation to provide financial resources for the Company to continue execution of its strategy to further progress development of its three high-priority pipeline programs, including IXEMPRA®, stenoparib and dovitinib.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Ixabepilone

            Therapeutic Area: Oncology Product Name: Ixempra

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Negma Group LTD

            Deal Size: $1.2 million Upfront Cash: Undisclosed

            Deal Type: Financing December 22, 2020

            Details:

            This financing, under the called tranche, serves as a foundation to provide financial resources for the Company to continue execution of its strategy to further progress development of its three high-priority pipeline programs, including IXEMPRA®, stenoparib and dovitinib.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Ixabepilone

            Therapeutic Area: Oncology Product Name: Ixempra

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Negma Group

            Deal Size: $11.7 million Upfront Cash: Undisclosed

            Deal Type: Financing November 05, 2020

            Details:

            This financing, under the called tranche, serves as a foundation to provide financial resources for the Company to continue execution of its strategy to further progress development of its three high-priority pipeline programs, including IXEMPRA®, stenoparib and dovitinib.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Daratumumab

            Therapeutic Area: Oncology Product Name: Darzalex

            Highest Development Status: Approved Product Type: Large molecule

            Partner/Sponsor/Collaborator: Janssen Pharmaceutical

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 21, 2020

            Details:

            Second part of the Phase 3 CASSIOPEIA study of daratumumab as maintenance treatment for patients with newly diagnosed multiple myeloma eligible for autologous stem cell transplant met the primary endpoint of progression-free survival at a pre-planned interim analysis.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Daratumumab

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Approved Product Type: Large molecule

            Partner/Sponsor/Collaborator: Janssen Ortho LLC

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration January 22, 2020

            Details:

            The license agreement terms for Janssen Biotech, Inc. to develop, manufacture and market DARZALEX under the exclusive worldwide license.